DLL3在80%的SCLC患者中高表达,为靶向治疗提供了较好的解决方案。目前针对该靶点仅1款产品获批上市,竞争格局好。随着该领域未来越来越多管线 ...
开源证券发布研报称,SCLC侵袭性较强、预后相对较差,目前二三线治疗缺乏有效靶向治疗药物。DLL3在80%的SCLC患者中高表达,为靶向治疗提供了较好的解决方案。目前针对该靶点仅1款产品获批上市,竞争格局好。随着该领域未来越来越多管线布局及早研数据读出 ...
12月29日,恒瑞医药宣布,将公司自主研发的Delta样配体3(DLL3) ADC创新药SHR-4849在除大中华区以外的全球范围内开发、生产和商业化的独家权利有偿许可 ...
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement ...
Their findings highlighted promising results for two of the analyzed biomarkers: Delta-like ligand 3 (DLL3) and Thyroid transcription factor-1 (TTF-1). DLL3 was identified in over 70% of the ...
Ltd. for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program. Under deal terms, IDEAYA will develop and commercialize SHR-4849 worldwide outside of Greater China. The company stated that ...